NASDAQ:CADL

Candel Therapeutics Stock Forecast, Price & News

$10.49
+0.47 (+4.69 %)
(As of 09/23/2021 11:48 AM ET)
Add
Compare
Today's Range
$10.34
$10.50
50-Day Range
$5.75
$11.21
52-Week Range
$5.51
$14.78
Volume1,481 shs
Average Volume164,116 shs
Market Capitalization$300.96 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CADL News and Ratings via Email

Sign-up to receive the latest news and ratings for Candel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Candel Therapeutics logo

About Candel Therapeutics

Candel Therapeutics Inc. is a late clinical stage biopharmaceutical company. It involved in developing novel oncolytic viral immunotherapies. The company's product pipeline includes CAN-2409 and CAN-3110. Candel Therapeutics Inc. is based in NEEDHAM, Mass.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.70 out of 5 stars

Medical Sector

901st out of 1,352 stocks

Biological Products, Except Diagnostic Industry

139th out of 193 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Candel Therapeutics (NASDAQ:CADL) Frequently Asked Questions

Is Candel Therapeutics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Candel Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Candel Therapeutics stock.
View analyst ratings for Candel Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Candel Therapeutics?

Wall Street analysts have given Candel Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Candel Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Candel Therapeutics?

Candel Therapeutics saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 60,400 shares, an increase of 571.1% from the August 15th total of 9,000 shares. Based on an average trading volume of 207,900 shares, the short-interest ratio is currently 0.3 days. Currently, 0.6% of the company's stock are short sold.
View Candel Therapeutics' Short Interest
.

When is Candel Therapeutics' next earnings date?

Candel Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, December 8th 2021.
View our earnings forecast for Candel Therapeutics
.

How were Candel Therapeutics' earnings last quarter?

Candel Therapeutics, Inc. (NASDAQ:CADL) issued its quarterly earnings data on Wednesday, September, 8th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.36) by $0.05. The business had revenue of $0.03 million for the quarter.
View Candel Therapeutics' earnings history
.

What price target have analysts set for CADL?

3 brokers have issued 1 year target prices for Candel Therapeutics' shares. Their forecasts range from $9.00 to $22.00. On average, they expect Candel Therapeutics' stock price to reach $15.33 in the next year. This suggests a possible upside of 46.2% from the stock's current price.
View analysts' price targets for Candel Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are some of Candel Therapeutics' key competitors?

When did Candel Therapeutics IPO?

(CADL) raised $72 million in an IPO on Tuesday, July 27th 2021. The company issued 9,000,000 shares at $8.00 per share. Jefferies, Credit Suisse, BMO Capital Markets and UBS Investment Bank acted as the underwriters for the IPO.

What is Candel Therapeutics' stock symbol?

Candel Therapeutics trades on the NASDAQ under the ticker symbol "CADL."

When did the company's quiet period expire?

Candel Therapeutics' quiet period expired on Monday, September 6th. Candel Therapeutics had issued 9,000,000 shares in its IPO on July 27th. The total size of the offering was $72,000,000 based on an initial share price of $8.00. During the company's quiet period, underwriters and any insiders involved in the IPO were prevented from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Candel Therapeutics?

Shares of CADL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Candel Therapeutics' stock price today?

One share of CADL stock can currently be purchased for approximately $10.49.

How much money does Candel Therapeutics make?

Candel Therapeutics has a market capitalization of $300.96 million.

How many employees does Candel Therapeutics have?

Candel Therapeutics employs 2,021 workers across the globe.

What is Candel Therapeutics' official website?

The official website for Candel Therapeutics is www.candeltx.com.

How can I contact Candel Therapeutics?

The company can be reached via phone at 617-916-5445 or via email at [email protected].


This page was last updated on 9/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.